Zerigo Health, a San Diego, CA-based provider of a connected light therapy solution for treating chronic skin conditions at home or on the go, raised $43m in Series B funding.
The round was led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer, as well as SV Health Investors, H.I.G. Capital, and Bluestem Capital. Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.
The company intends to use the funds to respond to expand its business reach.
Led by John E. Schellhorn, President and CEO, Zerigo provides an innovative connected chronic skin condition solution to Americans living with psoriasis, vitiligo, and eczema. Its FDA-cleared, natural light therapy solution shifts dermatological care from the clinic to the controlled convenience of home, keeping physicians and their patients with chronic skin conditions connected with personalized data and insights. Patients can self-administer clinically proven, American Academy of Dermatology guideline recommended narrowband ultraviolet B (NB-UVB) phototherapy using a handheld device and smartphone app. Prescription dosing is controlled via secure cloud-based technology, and patients are also remotely monitored and given personal coaching and support throughout their treatment journey.